SEP 02, 2012
2012 Annual Scientific Meeting of the American Society of Retina Specialists
Dr. Pravin U. Dugel discusses a recent study showing that patients with neovascular AMD treated with a combination of Fovista (Ophthotec), an anti-platelet-derived growth factor (anti-PDGF) agent, and ranibizumab achieved a 62% relative visual benefit over anti-VEGF monotherapy. Dr. Dugel presented phase 2B study results at the 2012 Annual Scientific Meeting of the American Society of Retina Specialists (ASRS).
Dr. Dugel receives consulting fees from Abbott Medical Optics, Alcon Laboratories, Allergan, Arctic Dx, Genentech, Macusight, Neovista, ORA, Regeneron Pharmaceuticals, and ThromboGenics.